External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Dr. Reddy's Laboratories / Equity Bottom-Up

<ul><li>Dr Reddy Q2FY22 reported revenue growth of 9.4% YoY which stood above our expectations. </li><li>The growth was driven by the launch of gRevlimid in the US and sequential improvement in Russian sales, which was only partially offset by price erosion in the generic business.</li><li>The US sales of $354 Mn, comprising $125 Mn from gRevlimid, are expected to be on the lower side.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Dr Reddy Q2FY22 reported revenue growth of 9.4% YoY which stood above our expectations. The growth was driven by the launch of gRevlimid in the US and sequential improvement in Russian sales, which was only partially offset by price erosion in the generic business.The US sales of $354 Mn, comprising $125 Mn from gRevlimid, are expected to be on the lower side.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Dr. Reddy’s Laboratories Ltd - New Launches to Add Growth and Profitability!